ePrints

Denosumab-induced hypocalcaemia in metastatic gastric cancer

Lookup NU author(s): Dr Richard Quinton, Dr Donna WakefieldORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© Author(s) (or their employer(s)) 2024. Hypocalcaemia in malignancy is infrequently reported and the underlying cause is often multifactorial. Denosumab, an antiresorptive medication, can be used to treat a number of cancer-related complications including hypercalcaemia, metastatic bone pain and to reduce fracture-events. We present a case of a hospice inpatient with profound and recurring hypocalcaemia following a single denosumab infusion which required repeated hospitalisation, for intravenous calcium, alongside a prolonged course of vitamin D and electrolyte replacement. The case highlights the risk of hypocalcaemia with denosumab use, together with the need to identify and treat vitamin D deficiency in both the prevention and management of such a complication.

Publication metadata

Author(s): Gouldthorpe C, Quinton R, Wakefield D

Publication type: Article

Publication status: Published

Journal: BMJ Supportive and Palliative Care

Year: 2024

Volume: 14

Issue: e2

Pages: e1762-e1764

Print publication date: 01/11/2024

Online publication date: 27/08/2020

Acceptance date: 20/07/2020

ISSN (print): 2045-435X

ISSN (electronic): 2045-4368

Publisher: BMJ Publishing Group

URL: https://doi.org/10.1136/BMJSPCARE-2020-002548

DOI: 10.1136/BMJSPCARE-2020-002548

PubMed id: 32855233

Altmetrics

Share